60 Degrees Pharmaceuticals, Inc.
SXTPW· Nasdaq
SXTPW60 Degrees Pharmaceuticals, Inc.
Source filing unavailable
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Revenue | $17.17K | — |
| Net Income | -$2.60M | -$907.45K |
| EPS Diluted | -$1.13 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
60 Degrees Pharmaceuticals, Inc. · CIK 1946563 · Engraved from SEC EDGAR
